as well as to test amyloid plaque development in animal models representing MS. More information: Matthew R. Brier et al, Unexpected Low Rate of Amyloid‐β Pathology in Multiple Sclerosis ...
Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.